Abbott Laboratories (ABT) financials

NYSE · Healthcare · Medical - Devices · 115,000 employees · CEO Robert Ford

Price: $106.20 +1.56%
Market cap: $184B
Enterprise value: $211B
Last report: Q3 '26 filed 2026-09-30
Next report: 2027-01-28 EPS est. $1.64

Revenue (TTM)$48.2B+10.0% vs a year agoLast 4 quarters; bars = each quarter

Operating margin (TTM)15.2%-2.5 pp vs a year agoOperating income $7.35B

Net income (TTM)$4.7B-66.4% vs a year agoAfter tax, incl. non-operating gains

Free cash flow (TTM)–– vs a year agoCapex –

Diluted EPS (TTM)$2.70-66.2% vs a year agoSum of the last 4 quarters

Net cash-$27B-338.7% vs a year agoCash + short-term investments - debt

Valuation & key figures

Market cap: $184B
Revenue: $48.2B
Revenue growth: +13%
Profit margin: 9.7%
P/E: 39.3×
P/S: 3.8×
EV / EBITDA: 21.8×
Free cash flow: –
Net income: $4.7B
Revenue estimate: $50B
Earnings: 2027-01-28
Dividend: $2.52

Key takeaways

Computed from the reported numbers - every statement carries the figure it rests on.

Last report (2026-10-21): revenue in line, EPS in lineRevenue $13B vs $13B expected (+0.2%); EPS $1.42 vs $1.42 (0.0%).
Revenue growth accelerating: 14.5% year on yearQ3 '26 revenue $13B, against an average of 8.0% over the four quarters before.
Operating margin 15.2% (TTM), -2.5 pp on a year agoOperating income grew -5.6% while revenue grew 10.0%.
12.0% of pre-tax profit is eaten by non-operating lossesPre-tax income $6.56B vs operating income $7.35B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.
Diluted share count down 0.6% in a year1.74B diluted shares in Q3 '26, 1.75B a year earlier.
Net debt $27BCash + short-term investments $5.6B, debt incl. leases $32.6B; a year ago net debt $6.16B.

Last quarter: Q3 '26

Quarter ended 2026-09-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.

Quarter vs a year ago

	Q3 '26	Year ago	Change
Revenue	$13B	$11.4B	+14.5%
Gross margin	57.1%	55.7%	+1.3 pp
Operating income	$1.48B	$2.06B	-28.2%
Operating margin	11.3%	18.1%	-6.8 pp
Net income	$920M	$1.64B	-44.0%
Diluted EPS	$0.53	$0.94	-43.6%
Operating cash flow	–	$2.79B	–
Capex	–	$496M	–
Free cash flow	–	$2.29B	–
R&D	$908M	$785M	+15.7%
Stock-based compensation	–	$120M	–

Reported vs consensus

2026-10-21

	Actual	Consensus	vs consensus
Revenue	$13B	$13B	+0.2%
EPS (as estimated)	$1.42	$1.42	0.0%

From the report of 2026-10-21 for Q3 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.

EPS vs consensus

last 8 reports

Revenue

Where the money comes from - by business line and by region, quarter by quarter.

Revenue, operating income and growth

quarterly

Revenue by business line

stacked, quarterly

Segment	Q2 '26	y/y	Share	TTM	TTM y/y
Diagnostic Products	$3.09B	-47.6%	24.6%	$11.3B	-12.5%
Medical Devices	$5.85B	+9.0%	46.5%	$22.5B	+12.2%
Nutritional Products	$2.14B	-3.1%	17.0%	$8.25B	-3.5%
Established Pharmaceutical Products	$1.5B	+8.4%	11.9%	–	–
Established Pharmaceuticals	–	–	–	–	–
Other	$5M	–	0.0%	–	–

Revenue by region

share of total

Segment	Q2 '26	y/y	Share	TTM	TTM y/y	12 quarters
Non-US	$7.38B	+7.4%	58.6%	$21.3B	-18.3%
United States	$5.22B	+22.0%	41.4%	$18.2B	+7.0%

Segment profits

Operating income per reported segment, read from the segment note of each 10-Q / 10-K (the profit split most data feeds leave out).

Segments in Q2 '26

Segment	Revenue	y/y	Operating income	y/y	Margin	Margin a year ago	TTM operating income
Established Pharmaceutical Products	–	–	$382M	+10.4%	–	–	$1.39B
Nutritional Products	–	–	$368M	-12.0%	–	–	$1.43B
Diagnostic Products	–	–	$499M	+34.1%	–	–	$1.84B
Medical Devices	–	–	$1.97B	+9.6%	–	–	$7.67B

Operating income by segment

quarterly

Segment operating margin

quarterly

Fourth quarters are derived: the 10-K reports the full year, minus the three quarters of the 10-Qs.

Margins & cost structure

How much of each unit of revenue is left at each level - and where the costs go.

Margins

quarterly

Costs as % of revenue

quarterly

Cash flow & capital allocation

Cash generated, what it is spent on, and what reaches shareholders.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Last 4 quarters

cash flow statement

Free cash flow: –
Returned to shareholders / FCF: –

Share count and EPS

quarterly, diluted

Balance sheet

Liquidity, investments and debt at each quarter end.

Cash, investments and debt

quarter ends

Valuation & returns

Today's multiples against the company's own last five fiscal years; analyst targets and ratings.

Multiples and returns

TTM vs 5 fiscal years

	Now	5y average	Where today sits in the 5-year range
P/E (TTM)	39.3×	29.0×	14.7× – 35.5×
EV / EBITDA	21.8×	18.9×	16.9× – 21.3×
EV / Sales	4.4×	5.1×	4.6× – 6.0×
Price / FCF	21.1×	30.3×	24.7× – 37.7×
Price / Book	3.6×	5.1×	4.1× – 7.0×
FCF yield	4.7%	3.4%	2.7% – 4.1%
Return on invested capital	5.6%	10.3%	8.4% – 12.6%
Return on equity	9.1%	18.8%	12.5% – 28.1%

Analysts

Consensus target $121.36 (+14.3%)
range $112.00 – $130.00 · rating Buy

Strong buy0

Buy33

Hold10

Sell0

Strong sell0

Outlook

Analyst consensus for the coming fiscal years and what it implies at today's price.

Consensus estimates

Fiscal year	Revenue	Growth	EPS	Growth	P/E at today's price	Analysts (EPS)
FY2026	$50B	+12.8%	$5.52	+48.3%	19.2×	17
FY2027	$53.7B	+7.4%	$5.93	+7.6%	17.9×	18
FY2028	$57.1B	+6.5%	$6.50	+9.5%	16.3×	14
FY2029	$61.4B	+7.5%	$7.21	+10.8%	14.7×	7
FY2030	$65.8B	+7.1%	$7.94	+10.2%	13.4×	11

Financial statements

Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.

Income statementRevenue, costs, operating income, net income and EPSOpen Balance sheetCash, investments, assets, debt, liabilities and equityOpen Cash flowOperating cash flow, capex, free cash flow, buybacks and dividendsOpen

Every reported line

All 232 figures Abbott Laboratories tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).

Line (SEC label)	Latest quarter	Year ago	y/y	Latest FY	Prior FY	y/y
Accounts Payable, Trade, Current	$4.68B	$4.21B	+11.0%	$4.24B	$4.2B	+1.1%
Accounts Receivable, after Allowance for Credit Loss, Current	$8.21B	$7.33B	+12.1%	$7.93B	$6.93B	+14.5%
Accounts Receivable, Allowance for Credit Loss	$310M	$259M	+19.7%	$290M	$247M	+17.4%
Accounts Receivable, Allowance for Credit Loss, Current	$494M	$449M	+10.0%	$490M	$439M	+11.6%
Accounts Receivable, Allowance for Credit Loss, Writeoff	$6M	$11M	-45.5%	$32M	$55M	-41.8%
Accounts Receivable, Credit Loss Expense (Reversal)	$26M	$23M	+13.0%	$75M	$61M	+23.0%
Accrued Income Taxes, Current	$598M	$485M	+23.3%	$569M	$594M	-4.2%
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$13.4B	$12.5B	+7.0%	$13.4B	$12.1B	+11.0%
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax	$14M	$581M	-97.6%	$1M	$611M	-99.8%
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	-$6.33B	-$6.96B	+9.0%	-$5.93B	-$7.51B	+21.0%
Accumulated Other Comprehensive Income (Loss), Net of Tax	-$6.31B	-$7.42B	+14.9%	-$6B	-$7.91B	+24.1%
Amortization of Intangible Assets	$422M	$420M	+0.5%	$1.68B	$1.88B	-10.4%
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	9.9M	1.43M	+591.8%	1M	7M	-85.7%
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax	$33M	$119M	-72.3%	-$69M	$210M	-132.9%
Assets	$110B	$81.4B	+35.6%	$86.7B	$81.4B	+6.5%
Assets, Current	$25.5B	$23.2B	+10.2%	$26B	$23.7B	+9.9%
Assets, Fair Value Disclosure	$575M	–	–	$450M	$714M	-37.0%
Buildings and Improvements, Gross	$4.54B2025-12-31	$4.21B	+8.0%	$4.54B	$4.21B	+8.0%
Business Combination, Contingent Consideration, Liability	$304M	–	–	$1M	$38M	-97.4%
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual	$96M	–	–	–	–	–
Cash and Cash Equivalents, at Carrying Value	$6.8B	$6.53B	+4.1%	$8.52B	$7.62B	+11.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$6.8B	$6.53B	+4.1%	$8.52B	$7.62B	+11.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	-$1.72B	-$1.08B	-58.6%	$906M	$720M	+25.8%
Common Stock, Dividends, Per Share, Declared	$0.63	$0.59	+6.8%	$2.40	$2.24	+7.1%
Common Stock, Shares Authorized	2.4B	2.4B	0.0%	2.4B	2.4B	0.0%
Common Stock, Shares, Issued	2B	2B	+0.1%	2B	1.99B	+0.3%
Common Stock, Value, Issued	$25.4B	$25.1B	+0.9%	$25.5B	$25.2B	+1.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$766M	$1.81B	-57.8%	$8.43B	$13.3B	-36.8%
Construction in Progress, Gross	$2.57B2025-12-31	$2.49B	+3.2%	$2.57B	$2.49B	+3.2%
Contract with Customer, Liability	$660M	$601M	+9.8%	$633M	$568M	+11.4%
Contract with Customer, Liability, Revenue Recognized	$123M	$99M	+24.2%	-$423M	-$460M	+8.0%
Cost of Goods and Services Sold	$4.89B	$4.47B	+9.4%	$19.3B	$18.7B	+3.3%
Costs and Expenses	$9.82B	$8.67B	+13.3%	$36.3B	$35.1B	+3.3%
Current Federal Tax Expense (Benefit)	–	–	–	$302M	–	–
Current Federal, State and Local, Tax Expense (Benefit)	–	–	–	$85M	$497M	-82.9%
Current Foreign Tax Expense (Benefit)	–	–	–	$1.11B	$1.08B	+3.6%
Current Income Tax Expense (Benefit)	–	–	–	$1.5B	$1.57B	-4.5%
Current State and Local Tax Expense (Benefit)	–	–	–	$0	$497M	-100.0%
Deferred Federal Income Tax Expense (Benefit)	–	–	–	-$217M	–	–
Deferred Federal, State and Local, Tax Expense (Benefit)	–	–	–	-$40M	-$459M	+91.3%
Deferred Foreign Income Tax Expense (Benefit)	–	–	–	$698M	-$7.5B	+109.3%
Deferred Income Tax Expense (Benefit)	–	–	–	$441M	-$7.96B	+105.5%
Deferred Income Taxes and Other Assets, Noncurrent	$18.4B	$16.8B	+9.0%	$18.4B	$16.5B	+11.9%
Deferred State and Local Income Tax Expense (Benefit)	–	–	–	$0	-$459M	+100.0%
Deferred Tax Assets, Gross	$11.6B2025-12-31	$12.1B	-3.9%	$11.6B	$12.1B	-3.9%
Deferred Tax Assets, in Process Research and Development	$902M2025-12-31	$773M	+16.7%	$902M	$773M	+16.7%
Deferred Tax Assets, Inventory	$146M2025-12-31	$168M	-13.1%	$146M	$168M	-13.1%
Deferred Tax Assets, Net	$7.51B2025-12-31	$8.11B	-7.5%	$7.51B	$8.11B	-7.5%
Deferred Tax Assets, Net of Valuation Allowance	$9.83B2025-12-31	$10.4B	-5.5%	$9.83B	$10.4B	-5.5%
Deferred Tax Assets, Other	$9.73B2025-12-31	$10.4B	-6.0%	$9.73B	$10.4B	-6.0%
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts	$227M2025-12-31	$230M	-1.3%	$227M	$230M	-1.3%
Deferred Tax Assets, Valuation Allowance	$1.77B2025-12-31	$1.66B	+6.4%	$1.77B	$1.66B	+6.4%
Deferred Tax Liabilities, Gross	$2.33B2025-12-31	$2.3B	+1.3%	$2.33B	$2.3B	+1.3%
Deferred Tax Liabilities, Other	$1.06B2025-12-31	$1.37B	-22.6%	$1.06B	$1.37B	-22.6%
Deferred Tax Liabilities, Property, Plant and Equipment	$489M2025-12-31	$408M	+19.9%	$489M	$408M	+19.9%
Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation	$1.28B2025-12-31	$1.18B	+8.1%	$1.28B	$1.18B	+8.1%
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets	$152M2025-12-31	$149M	+2.0%	$152M	$149M	+2.0%
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation	$1.28B2025-12-31	$1.18B	+8.1%	$1.28B	$1.18B	+8.1%
Defined Benefit Plan, Plan Assets, Amount	$16.6B2025-12-31	$14.4B	+15.0%	$16.6B	$14.4B	+15.0%
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation	$1.2B2025-12-31	$1.11B	+7.6%	$1.2B	$1.11B	+7.6%

Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.

Sources

Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30

Data as of 2026-11-01